Archived documents
Documents past their public comment period for Pharmaceutical Policy.
Determination That PYRIDOSTIGMINE BROMIDE Tablets, 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
0 comments
Analysis in progress
Top issues in comments
Letter from FDA CDER to Lachman Consultant Services, Inc.
0 comments
Analysis in progress
Top issues in comments
"Determination That LOVENOX (Enoxaparin Sodium) 90 Milligrams/0.6 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
0 comments
Analysis in progress
Top issues in comments
PSG_020503 - Draft Guidance on Albuterol Sulfate
0 comments
Analysis in progress
Top issues in comments
PSG_214070 - Draft Guidance on Albuterol Sulfate; Budesonide
0 comments
Analysis in progress
Top issues in comments
PSG_219423 - Draft Guidance on Amlodipine Besylate; Indapamide; Telmisartan
0 comments
Analysis in progress
Top issues in comments
PSG_210745 - Draft Guidance on Apremilast
0 comments
Analysis in progress
Top issues in comments
PSG_202971 - Draft Guidance on Aripiprazole
0 comments
Analysis in progress
Top issues in comments
PSG_218643 - Draft Guidance on Articaine Hydrochloride
0 comments
Analysis in progress
Top issues in comments
PSG_219208 - Draft Guidance on Atrasentan Hydrochloride
0 comments
Analysis in progress
Top issues in comments
PSG_219616 - Draft Guidance on Avutometinib Potassium; Defactinib Hydrochloride
0 comments
Analysis in progress
Top issues in comments
PSG_207921 - Draft Guidance on Beclomethasone Dipropionate
0 comments
Analysis in progress
Top issues in comments